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Abstract
Background: Depression is a global health challenge. Although there are effective psychological and pharmaceutical
interventions, our best treatments achieve remission rates less than 1/3 and limited sustained recovery. Underpinning
this efficacy gap is limited understanding of how complex psychological interventions for depression work. Recent
reviews have argued that the active ingredients of therapy need to be identified so that therapy can be made briefer,
more potent, and to improve scalability. This in turn requires the use of rigorous study designs that test the presence
or absence of individual therapeutic elements, rather than standard comparative randomised controlled trials. One
such approach is the Multiphase Optimization Strategy, which uses efficient experimentation such as factorial designs
to identify active factors in complex interventions. This approach has been successfully applied to behavioural health
but not yet to mental health interventions.
Methods/Design: A Phase III randomised, single-blind balanced fractional factorial trial, based in England and
conducted on the internet, randomized at the level of the patient, will investigate the active ingredients of
internet cognitive-behavioural therapy (CBT) for depression. Adults with depression (operationalized as PHQ-9
score ≥ 10), recruited directly from the internet and from an UK National Health Service Improving Access to
Psychological Therapies service, will be randomized across seven experimental factors, each reflecting the
presence versus absence of specific treatment components (activity scheduling, functional analysis, thought
challenging, relaxation, concreteness training, absorption, self-compassion training) using a 32-condition
balanced fractional factorial design (2IV
7-2). The primary outcome is symptoms of depression (PHQ-9) at
12 weeks. Secondary outcomes include symptoms of anxiety and process measures related to hypothesized
mechanisms.
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Discussion: Better understanding of the active ingredients of efficacious therapies, such as CBT, is necessary in order
to improve and further disseminate these interventions. This study is the first application of a component selection
experiment to psychological interventions in depression and will enable us to determine the main effect of each
treatment component and its relative efficacy, and cast light on underlying mechanisms, so that we can systematically
enhance internet CBT.
Trial registration: Current Controlled Trials ISRCTN24117387. Registered 26 August 2014
Keywords: Online, Cognitive behavioural therapy, Depression, MOST, Factorial
Background
Depression is a major global health challenge [1, 2]: it is
highly prevalent, recurrent [3] and a leading cause of
disability worldwide, with enormous individual, societal,
and economic burden [4]. Although both antidepressant
medication and cognitive-behavioural therapy (CBT) are
evidence-based and recommended treatments for depres-
sion, there is still a major treatment gap. First, even these,
our best treatments, only achieve remission rates of less
than 1/3 and limited sustained recovery (50–80 % relapse/
recurrence) [5] (an efficacy gap). Second, there is sub-
optimal adherence to antidepressants and patients express
a preference for psychological interventions (a preference
gap). Third, traditional face-to-face psychotherapy can
never be sufficiently widely available to reduce the global
burden of depression, indicating the need for alternative
delivery methods [5, 6] (a scalability gap).
One solution to address the scalability gap is via
internet-based or e-therapy. Internet-CBT for depression
has comparable efficacy to face-to-face treatment when
supported by a therapist [7], can increase access by
removing time constraints and geographical restrictions to
attending therapy [7], and can increase cost-effectiveness
and treatment coverage [8] by reducing therapist treat-
ment time. Effective unguided e-therapy would have
almost no constraints on volume of use and would be
globally scalable and accessible.
Underpinning the efficacy gap is limited understanding of
how complex psychological interventions for depression
work. Resolving the active mechanisms of psychological
interventions has been identified as a major priority
[5, 9–11]. Uncovering the mechanisms of psycho-
logical treatments and optimising the content and
delivery of treatments is necessary to build more
potent, scalable, and efficient treatments. Because
little progress has been made in specifying the active
ingredients of CBT for depression [5, 9, 10], there have
been no significant gains in the effectiveness of CBT for
depression for over 30 years. Recent reviews have argued
that we need to identify active elements so that therapy
can be parsed and distilled to focus on what is essential
and most engaging to patients, making it briefer, more
potent, and facilitating wider dissemination and coverage
[11, 12]. The Institute of Medicine recently proposed that
determination of which elements are critical depends on
testing the presence or absence of individual therapeutic
elements in rigorous study designs [12].
One reason for limited progress in understanding
mechanisms is the overreliance on parallel group
comparative randomised controlled trials (RCTs).
Such RCTs are effective for establishing the relative
efficacy of one treatment intervention versus another,
where they provide the gold standard for determining
if an intervention works. However, they are limited at
investigating the specific mechanisms of how inter-
ventions work because they can only compare the
overall effects of each intervention package. Psycho-
logical treatments such as CBT are complex interven-
tions, typically made up of multiple elements and
components, each of which potentially acts via distinct
mechanisms.
In standard comparative RCTs, all treatment components
and their closely related hypothetical mechanisms are
aggregated and confounded together in the comparison of
treatment conditions. As a consequence, this design is
unable to test specific main effects of treatment compo-
nents and any possible synergistic or antagonistic interac-
tions between individual treatment components, limiting
advances in mechanistic understanding. If an RCT finds
one treatment better than another, we don’t know which
components made a difference; if there is no difference, we
don’t know whether there are any components that effected
an improvement.
Instead, we propose an innovative approach to begin to
address both the scalability and efficacy gaps by using a
fractional factorial design for the first time to identify the
active ingredients within internet-delivered CBT for depres-
sion (the IMPROVE-2 study; Implementing Multifactorial
Psychotherapy Research in Online Virtual Environments).
This approach directly responds to the Institute of
Medicine’s (2015) call for rigorous trial design to disentan-
gle specific therapy elements.
Our approach is a theory-driven component selection
experiment framed within the Multiphase Optimization
Strategy (MOST) [13–19] approach. MOST, rooted in
engineering, agriculture, and behavioural science, is a
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principled and comprehensive framework for optimizing
and evaluating behavioural interventions [13–15].
The optimization phase of MOST uses efficient
experimentation to identify which of a set of candidate
components is effective and should be included in the
optimized intervention. Although a wide variety of
experimental designs are possible candidates for use in the
optimization phase, frequently factorial or fractional
factorial designs emerge as most efficient [14, 15, 20].
Factorial and fractional factorial experiments allow one to
explore main effects of factors and interactions among
factors [20]. A fractional factorial design is a variation on
the factorial design that employs a systematic approach to
reduce the number of experimental conditions to allow a
more manageable study, at the cost of allowing only main
effects and a pre-specified set of interactions to be tested.
Fractional factorial designs require the assumption that
higher-order interactions are negligible in size, because
they are combined, or aliased, with lower-order effects.
In the evaluation phase of MOST, the optimized inter-
vention, constructed based on the findings from the
optimization phase and assembled to meet a specific
optimization criterion, is compared against a control
intervention in a standard RCT.
Critically, the optimization phase proposed by MOST
[13] provides direct evidence about the effects and interac-
tions of individual components within a treatment package,
which is necessary for methodically enhancing and simpli-
fying complex interventions [21]. This approach enables us
to develop a mechanistic understanding of therapy and to
select active and reject inactive/counter-productive compo-
nents or elements.
MOST is well-validated [13, 22–25] and recommended
within the Medical Research Council Complex Interven-
tion guidelines [26]. A key advantage is greater experi-
mental efficiency, with a focus on identifying “active
ingredients” versus “inactive” or extraneous components
before moving onto large-scale comparative trials, result-
ing in fewer overall resources required to answer the
research questions in the long run than with the
traditional approach [27]. However, to date, MOST has
not been applied to psychological interventions for
mental health.
In the current study, we therefore will combine the
MOST approach with an e-health delivery format for CBT
to build in treatment reach, scalability, and increased
treatment coverage for the optimised treatment from the
beginning [6], as the goal is to develop an optimised
scalable evidence-based treatment. In addition,
internet-delivered therapy has the major advantage that
treatment content can be standardised and fixed, and
written therapist responses can be closely demarcated,
reducing unwanted “drift” from treatment protocols [7].
This helps prevent potential contamination between
different treatment components, an essential condition
for a factorial design.
Consistent with the MOST framework, we chose the
treatment components to ensure that they are conceptu-
ally and operationally distinct from each other, so that
each can be evaluated independently. This does not mean
that we assume that the treatment components do not
interact; we will use the factorial approach with effect cod-
ing as this allows us to concurrently test both main effects
and interactions [14, 17]. The current design assesses the
effectiveness of seven treatment components from stand-
ard CBT [28] and recent treatment innovations derived
from experimental research [29, 30], with each hypothe-
sized to specifically target distinct mechanisms arising
from different theoretical models. We will use a fractional
factorial design to retain the benefits of a factorial design
whilst making the study more logistically manageable and
feasible to deliver: the fractional factorial design reduces
the total number of conditions from 128 to 32.
IMPROVE-2 builds on a previous feasibility study
(IMPROVE-1), which assessed the feasibility of online
recruitment of patients with depression, of maintaining
treatment integrity and fidelity across randomisation into
multiple treatment conditions and of avoiding contamin-
ation across treatment conditions, and assessed rates of
attrition and retention and treatment adherence (Watkins,
Newbold, Cadman, Javaid, Umegaki, Collins, Graham &
Mostazir. Implementing multifactorial psychotherapy re-
search in online virtual environments (IMPROVE-1): a
feasibility trial of the MOST component selection experi-
ment for internet cognitive-behavioural therapy for depres-
sion, In preparation). IMPROVE 1 demonstrated that this
approach was feasible, and that it was possible to
randomize individuals into multiple treatment conditions
(32 in the fractional factorial design) without any contamin-
ation and with 100 % fidelity for the interventions received.
However, IMPROVE-1 was not powered to test main ef-
fects and interactions for each of the seven experimental
intervention factors on change in depression symptoms.
Aims and objectives
The primary aim of this phase III trial is to test the main
effects and selected interactions for seven treatment
components within internet CBT for depression. The
treatment components (in italics) and their associated
hypothesized mechanisms-of-action are described below.
Within the behavioural model, activity scheduling and
absorption training are hypothesized to increase response-
contingent positive reinforcement [31] by respectively
increasing frequency of positive reinforcement and direct
contact with positive reinforcers. Functional analysis is
proposed to target habitual avoidance and rumination by
identifying antecedent cues, controlling exposure to these
cues, and practising alternative responses to them [32].
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Within the cognitive model, thought challenging is
hypothesized to reduce the negative thinking characteristic
of depression [28]. Concreteness training [30] is hypothe-
sized to specifically reduce the overgeneralization cognitive
bias identified as important in depression [33].
Further treatment components are hypothesized to
improve emotional regulation. Relaxation is proposed to
target physiological arousal and tension. Self-compassion
training is proposed to activate the soothing and safe-
ness emotional system, hypothesized to be downregu-
lated in depression [34–36].
The use of a fractional factorial design will uniquely test
hypotheses from different theoretical models concerning
the mechanisms-of-action in internet CBT. By comparing
the presence versus absence of each component, this
factorial design can examine the main effect of each
component on the primary outcome (e.g., testing whether
thought challenging reduces symptoms of depression) and
on secondary outcome measures indexing the specific
mechanism theorised to be closely related to each compo-
nent (e.g., testing whether thought challenging has a main
effect on reducing self-reported negative cognition) and,
whether this in turn mediates the effect of the treatment
component on symptoms. Consistent with the Pareto
principle and prior MOST studies [23], we predict that
components and interactions will vary in treatment effect
size, with many insignificant (i.e., not all components are
active in therapeutic benefit of CBT). Watkins and Nolen-
Hoeksema (2014) predicted that treatment components
that explicitly target depressogenic habits by identifying
cueing stimuli and repeatedly training incompatible alter-
native responses (e.g., functional analysis) will have the
largest sustained treatment effect [32].
A further advantage of a factorial design is that it pro-
vides a strong test of the relative contribution of specific
versus non-specific common treatment factors. An import-
ant but as yet unresolved debate concerns the relative
contribution of non-specific common factors shared across
therapies (e.g., hope, remoralization, therapeutic alliance,
treatment credibility) versus specific elements (e.g., redu-
cing negative thinking, increasing behavioural activation).
CBT includes generic therapy elements (e.g., providing a
rationale, therapist support), and specific elements (e.g.,
activity scheduling, thought challenging), which are hypoth-
esized to act through different mechanisms. Identifying the
relative contribution of specific versus common factors has
major theoretical and practical implications for therapy
delivery. However, progress at disentangling specific from
non-specific treatment effects has been limited because of
difficulties in creating psychotherapy placebos (attentional
controls) that match the genuine psychotherapy for
credibility and structural equivalence [37]. In this factorial
design, for any treatment component (e.g. relaxation), the
aggregate of the 16 conditions where it is present (i.e.,
Table 1, conditions 17-32) are equivalent for treatment
credibility, structure, delivery, rationale, therapist contact,
and therapist allegiance with the aggregate of the 16 condi-
tions where it is absent (i.e., Table 1, conditions 1–16).
Hence, the evaluation of the main effect of relaxation in-
volves the comparison of the average effect for the condi-
tions where relaxation is present versus for the conditions
where relaxation is absent. This design therefore provides
an improved psychotherapy attentional control condition
able to disentangle specific from non-specific common
treatment factors. A significant main effect for any compo-
nent would be evidence for a specific treatment effect




A single centre, stratified (moderate depression, operation-
alized as PHQ-9 score < 20; severe depression, operational-
ized as PHQ-9 score > =20; source of recruitment: directly
from the internet versus within an National Health Service
Improving Access to Psychological Therapies (IAPT) treat-
ment service; antidepressant use: none versus at a recom-
mended clinical dose), block randomized, single-blind,
fractional factorial trial, based in England will be conducted
on the internet, randomized at the level of the patient. It
will be a full scale internet-delivered component selection
experiment with seven experimental factors evaluated, each
at two levels ((presence, coded as +1 versus absence, coded
as -1 of component; in other words, effect coded), using a
32-condition balanced fractional factorial design (2IV
7-2)).
This design will allow the estimation of all main effects and
several pre-specified 2-factor interactions among the seven
intervention factors; in statistical terminology, a Resolution
IV design because main effects are aliased with 3-way inter-
actions. Table 1 describes the specific combinations of 2-
level intervention factors in the experimental design. A full
factorial design of seven factors would have required 27 =
128 conditions; the fractional factorial design reduces the
total number of conditions by three-quarters.
Within the chosen fractional factorial design, all
participants will be randomized to receive at least one
component of CBT and in the majority of cases 3 or 4
components of CBT. This design does not have any
conditions in which participants receive no treatment
components, i.e., there is not a no-treatment, treatment-
as-usual, or waiting list control cell, making it suitable for
use in a clinical service. Main effects and interactions are
estimated based on aggregates across experimental condi-
tions. For each main effect, half of the study population
will be randomized to one level of the factor (e.g., condi-
tions 9–16, 25–32 presence of concreteness training) and
half will be randomized to the other level of the factor
(e.g., conditions 1–8, 17–24 absence of concreteness
Watkins et al. BMC Psychiatry  (2016) 16:345 Page 4 of 13
training); thus, the full sample size can be used to deter-
mine each of the main effects (and interactions), making
this design efficient for power and sample size.
Study settings
The study will be conducted over the internet and by tele-
phone with recruitment across all of England. In addition,
we will recruit within the IAPT service for the Cornwall
Partnership NHS Foundation trust. The intervention will
be delivered on the Internet, with the treatment being
supported by trained therapists or psychological wellbeing
practitioners (PWPs), either based in the University of
Exeter or within the IAPT service.
Participant inclusion criteria
Participants will be adults resident in England, registered
with a general practice, who (a) meet criteria for clinical
depression, as operationalized on the Patient Health
Questionnaire-9 (PHQ-9 ≥ 10) [38], a well-validated self-
report measure of depressive symptoms; (b) consent to
participate in the study; (c) are aged 18 or over; (d) are a
fluent English speaker; (e) have home or work access to
Table 1 Experimental groups of the fractional factorial design
Condition Functional Analysis Concrete training Compassion Absorption Relaxation Activity Scheduling Thought Challenging
1 no no no no no yes yes
2 yes no no no no no no
3 no no yes no no no no
4 yes no yes no no yes yes
5 no no no yes no yes no
6 yes no no yes no no yes
7 no no yes yes no no yes
8 yes no yes yes no yes no
9 no yes no no no no no
10 yes yes no no no yes yes
11 no yes yes no no yes yes
12 yes yes yes no no no no
13 no yes no yes no no yes
14 yes yes no yes no yes no
15 no yes yes yes no yes no
16 yes yes yes yes no no yes
17 no no no no yes no yes
18 yes no no no yes yes no
19 no no yes no yes yes no
20 yes no yes no yes no yes
21 no no no yes yes no no
22 yes no no yes yes yes yes
23 no no yes yes yes yes yes
24 yes no yes yes yes no no
25 no yes no no yes yes no
26 yes yes no no yes no yes
27 no yes yes no yes no yes
28 yes yes yes no yes yes no
29 no yes no yes yes yes yes
30 yes yes no yes yes no no
31 no yes yes yes yes no no
32 yes yes yes yes yes yes yes
Note: Every factor occurs an equal number of times at high and low levels (i.e. balanced) and all factors are orthogonal to each other. Each effect estimate
involves all 32 of the conditions in Table 1, thereby maintaining the power associated with all participants. This Resolution IV design means that all main effects
are aliased with 3-way and higher interactions, and all 2-way interactions are aliased with 2-way and higher interactions, on assumption that non-negligible 3-way
interactions are unlikely. In contrast, a standard RCT is aliased for all main effects and interactions of treatment components
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the Internet and an e-mail account that is used regularly;
(f ) are not currently enrolled in another psychological
therapy for depression or anxiety. Participants currently
receiving antidepressant medication will be eligible, pro-
vided the dosage has been stable for at least the previous
4 weeks.
In the IMPROVE 1 feasibility study, approximately 40 %
of individuals consented to the internet treatment but then
never logged onto the treatment or ceased the intervention
before completing the first module. To avoid this loss of
power and to optimise the number of treatment compo-
nents completed, which is central to our primary question
of which components are active, we will only randomise eli-
gible participants who complete an initial introductory wel-
come internet treatment module. This extra step will select
for participants who are motivated and engaged with inter-
net CBT and afford participants the opportunity to try out
the internet treatment approach and determine if it suits
them before committing to the trial.
Participant exclusion criteria
Participants will not be excluded for any other Axis I and
II diagnosis that may be co-morbid with depression e.g.,
anxiety disorders, eating disorders, personality disorders.
Participants with self-reported persistent self-injury,
current drug and alcohol problems, mania, paranoia, delu-
sions and hallucinations and active suicidality will be ex-
cluded from the trial and signposted to other online (e.g.,
Samaritans, befrienders) and NHS clinical support ser-
vices, and directed to their general practitioner.
Recruitment procedure
There will be two main recruitment pathways. The first
pathway will be through direct self-referral by potential
participants to the trial, principally via the internet. The
recruitment strategy will include websites, a Facebook page,
advertisements in social media, posters, flyers, web-links to
local and national depression support sites and charities,
articles in local newspapers, circulars through large
employers, and press releases. Participants who are inter-
ested in a trial of free online cognitive behavioural therapy
for depression will be directed to an online mood screening
website [https://mdcdepressionscreening.ex.ac.uk/], which
will provide further information on the study and which
includes online questionnaires organised in a conditional
logical flow to assess key eligibility criteria, such as depres-
sion (PHQ-9), suicidal ideation, current treatment, and
potential exclusion criteria. Automated feedback will
inform participants whether they are eligible for further
screening, for example, whether they meet the study criteria
for elevated symptoms of depression (PHQ-9 ≥ 10). Individ-
uals presenting with elevated suicidal ideation will be auto-
matically advised to see their GP and provided with contact
details for organisations offering support and advice.
Eligible participants are invited to leave their contact details
(name, telephone number, email address) as consent to be
contacted. Those participants who pass the screening phase
and indicate an interest in the study will be contacted for a
more detailed telephone interview to further explain the
study and confirm eligibility. At this stage, the full informa-
tion sheet and consent form are sent by email to the
participant.
The second recruitment pathway will be through the
NHS IAPT service for Anxiety and Depression in
Cornwall where the internet intervention will be
offered as part of the standard treatment protocol for
depression. For all referrals to the service, Psycho-
logical Wellbeing Practitioners (PWPs) conduct a
standardized telephone or face-to-face assessment to
confirm that the service is suitable for the patient’s
needs, which includes the PHQ-9. At the first available
opportunity after screening is complete, including
within this first assessment session, patients scoring
PHQ-9 > 10 who appear suitable for IMPROVE 2 trial
will be asked if they would like internet CBT and to
participate in research conducted by the Trust with
the University of Exeter. Participants indicating an
interest in the trial will have their contact details
passed to the research team who will contact them to
explain the study and proceed to the baseline
interview.
All participants who are eligible and consenting
will receive access, free of charge, to the internet
CBT platform via the web. Those who are eligible
and consent to participate will be sent an URL link
to the treatment platform and after logging in set
their own security password. Specific intervention
components received by participants will vary
according to the experimental condition to which
they were assigned.
Baseline and consent procedure
Telephone screening and baseline assessment
The baseline screening interview consists of brief
screening questions for alcohol and drug use, symptoms
of bipolar disorder and psychosis (Psychosis Screening
Questionnaire, PSQ [39]), assessment of any relevant
past or current treatments, and the Structured Clinical
Interview for DSM-IV (SCID-I; [40]) sections on current
and past depressive episodes, dysthymia, and generalised
anxiety disorder. In addition, questionnaires, delivered
either over the telephone or through an online survey or
by email or post, will be used to assess levels of worry
and rumination [41, 42], and symptom severity of
depression (PHQ-9) and generalized anxiety (GAD-7
[43]). Any risk reported during the interview will be
assessed using a well-established protocol to ensure
appropriate clinical support is obtained. Interviews will
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be audio-recorded, with the participant’s consent, so that
diagnostic status can be independently rated.
Consent to trial
All eligible participants will then be invited to enter the
trial and asked to return written consent to participate.
Once consent is received and the welcome treatment
module is completed, participants will be randomised
(see Fig. 1). People who do not fulfil the eligibility
criteria will be thanked for their time. Excluded partici-
pants are given feedback including advice to see their
GP and contact details of organisations for further
support, where relevant.
Randomisation and allocation concealment
Randomisation will be conducted by an independent off-
site statistician based within the Peninsula Clinical Trials
Unit using computer generated list of quasi-random
Fig. 1 Consort Flow Diagram for IMPROVE-2 study showing recruitment flow
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numbers. Participants will be randomised with equal
probability to the 32 conditions. Randomisation will be
stratified according to severity of current depression
(moderate PHQ-9 ≥ 10 and < 20 vs. severe PHQ-9 ≥ 20),
antidepressant use (receiving a BNF recommended
therapeutic dose versus not receiving a recommended
dose) and by source of referral (NHS referral vs direct
internet referral). All outcome assessors and data
analysts will be kept blind to treatment allocation. The
therapists will only have contact with the participant
during the intervention and will record the outcome
data and the nature and level of assistance given to each
participant during each module. In order to preserve
blinding of the study researcher, randomisation will be
conducted by a third party not involved in assessing or
treating the participants, who will also inform the
therapist, who will be responsible for informing partici-
pants of their allocation.
Sample size calculation
We assumed that the smallest Meaningful Clinical
Important Difference (MCID) would be a small effect
size (Cohen’s d or standardized mean difference = .2) for
the main effect of an individual treatment component or
interaction between components on pre-to-post change
in depression. Any smaller effect would be of little clin-
ical interest or value. In order to detect a MCID of d =
0.20 with 80 % power at α = 0.10 per treatment compo-
nent/interaction for pre-post change on depression, we
require a sample size of N = 632 (NQuery 7.0). Alpha of
0.1 is recommended for component selection experi-
ments to decrease the relative risk of Type II to Type I
error when selecting treatment components; i.e., to avoid
prematurely ruling out potentially active treatment com-
ponents [14, 17]. Conservatively estimating 40 % drop-
out attrition post-treatment, we require N ≈ 1056 for a
traditional ANOVA. However, because there are at least
five repeated measures on the primary outcome within
the treatment, we can use a latent growth curve model,
using mean scores as in ANOVA, which typically
requires 30-50 % fewer participants for the same power
[44]. Conservatively estimating that the use of growth
curve modelling effectively reduces our required sample
size by 30 % relative to only using first and last time-
point as in ANCOVA, we require N ≈ 736.
Intervention component factors
The content of the program will be based on CBT for
depression, programmed by the research team [https://
mindresolve.minddistrict.co.uk] hosted on an established
and secure internet-treatment platform provided by
MindDistrict, a Dutch internet health services company.
All participants will complete a welcome module which
includes a mood diary and basic psychoeducation about
depression prior to randomisation and then if rando-
mised will receive between 1 to 7 treatment components
depending on the randomized treatment condition.
Each module takes around an hour to complete in
session and 1-to-2 weeks to practise. Each treatment
component will include written psycho-education,
images, written vignettes, online experiential exercises
using audio-recordings with automatic feedback, down-
loadable audio exercises to practice skills, interactive
questionnaires, video vignettes of patients explaining
therapy, and response boxes in which patients write
about their experiences and plans. The modules each
follow the same basic structure: reflection on previous
session; introduction of new technique; practical exer-
cises and planning how to practise or implement the
technique in daily life. The intervention is accessed
through a secure website, with each participant having a
password protected account. Participants’ log-ins will be
automatically recorded by the programme, allowing for
an automated measure of treatment compliance.
Reminder emails will be sent to participants after two
weeks if they have not completed the module. The
participant can work through each module at his own
pace but can only move from one module to the next
once the therapist has provided feedback.
All components will involve brief prescribed therapist
online support to improve retention and adherence [7], in
which secure online written feedback is provided at the end
of each completed module, with the option for additional
secure messaging between therapist and patient. The coach
will highlight any positive steps made and encourage partic-
ipants to sustain these as well as pointing out areas to focus
on over the next module. Participants will also be able to
send questions to their assigned therapist throughout the
programme if they are having difficulty with a specific
exercise. Well-established self-report measures of anxious
and depression symptoms (PHQ-9, GAD-7) are presented
at the end of each component to assess symptom change.
Functional analysis
Functional analysis (FA) seeks to determine the func-
tions and contexts under which desired and unwanted
behaviours do and don’t occur and, thereby, find ways to
systematically increase or reduce these behaviours, by
exploring their antecedents, consequences, and variabil-
ity, and then either alter the environment to remove
antecedent stimuli that trigger unwanted behaviours
and/or practice incompatible and constructive alterna-
tive responses to these antecedents. This approach is
based on Behavioural Activation (BA) [45, 46] and
rumination-focused CBT [29, 47] approaches to depres-
sion. Within this module, patients complete question-
naires to identify their warning signs for stress and
rumination and to explore the consequences of their
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behaviour, make plans to alter environmental contingen-
cies that maintain stress, and generate “If Then” imple-
mentation intention plans to act differently to those
warning signs.
Relaxation
Within this module, a variant of progressive muscle
relaxation and breathing exercises is used to reduce
physiological arousal and tension in response to warning
signs, based on evidence that this intervention alone
reduces depression [30]. The module introduces a
rationale for relaxation, provides an online relaxation
exercise as a behavioural experiment to test if it reduces
tension, and a downloadable relaxation exercise.
Identifying and challenging negative thoughts
This module follows the standard steps within CBT for
depression as outlined in the 1979 Beck manual [28], in-
cluding psychoeducation about negative automatic
thoughts and cognitive distortions, vignettes of identify-
ing and challenging negative thoughts, and written exer-
cises in which patients practise identifying and then
challenging negative thoughts using thought records.
Activity scheduling
This module closely follows the activity scheduling
element of CBT for depression [28]. The internet
module provides psychoeducation about the negative
effects of avoidance, includes questionnaires to help
patients identify their own patterns of avoidance,
provides guidance on activity scheduling to build up
positive activities and reduce avoidance (e.g., breaking
plans into smaller steps; specifying when and where to
implement activities), and exercises in which partici-
pants generate their own activity plans.
Concreteness training
This module is based on the concreteness training
intervention found to reduce symptoms of depression
[30] and derived from experimental research indicat-
ing the benefits of shifting into a concrete processing
style [48, 49]. It provides psycho-education about
depression, rumination, and overgeneralization, a
behavioural experiment using audio-recorded exer-
cises to compare abstract versus concrete processing
styles, and downloadable audio exercises to practise
thinking about negative events in a concrete way. In
these exercises, patients identify a recent mildly to
moderately upsetting difficulty and work through stan-
dardized steps: (i) using mental imagery to focus on
sensory details during the difficult event, noticing
what is specific about the event and the context in
which it occurs; (ii) noticing the process and sequence
by which the difficult event unfolds (‘How did it
happen?’); (iii) focusing on how to move forward by
specifying the particular steps and behaviours to do
next.
Absorption training
Absorption training is focused on teaching an individual
to mentally engage and become immersed in what she is
doing in the present moment to improve her direct
connection with experience and enhance contact with
positive reinforcers. Within the module, patients complete
a behavioural experiment using audio-recorded exercises
to compare visualisations of memories of being absorbed
versus not being absorbed in a task, learn about flow [50],
practice generating a more absorbed mind-set using
downloadable audio exercises, and identify absorbing
activities.
Self-compassion training
Recent research has highlighted the potential benefit of
increasing self-compassion in treatments for depression
[29, 35, 36, 51]. Within this module, patients read
psychoeducation about compassion including useful self-
statements to encourage and support oneself, complete a
behavioural experiment that compares their own self-
talk to how they talk to others, try an audio-recorded
exercise visualising past experiences of self-compassion
to activate this mind-set and test its benefits, which is
downloadable for further practice, and identify activities
they would do more of and activities they would do less
of to be kinder to themselves.
The internet therapy will be provided by clinical
psychologists or qualified PWPs given specific training
in the internet CBT treatment approach. To ensure
treatment integrity and fidelity, there will be (a) 32
distinct programmed packages, one for each treatment
condition: each patient can access only the specific
package allocated, constraining patient and therapist
responses to the relevant treatment protocol and
ensuring identical content for all participants in each
condition; (b) scripted templates for therapist re-
sponses for each module provide the coach with con-
strained feedback faithful with the treatment model,
which they tailor to individual clients’ responses; (c)
checklists specifying allowed and prohibited elements
for each package; (d) extensive therapist training and
weekly supervision to a criterion standard; (e) All
responses from both client and therapist are automat-
ically saved by the online platform and a random
sample will be checked against the templates for
adherence and competence.
Blinding
This is a single blind study, with the researcher conducting
outcome measures blind to allocation. Participants will be
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asked at the end of the screening interview not to disclose
their allocation to the researcher in any of their future
correspondence with the researcher and reminded of the
importance of this prior to and during each follow-up inter-
view. Due to the intervention, participants and therapists
cannot be blinded. Because therapists are not blinded to
participant’s treatment, appropriate clinical steps can be
taken (e.g., withdrawing treatment, onward referral) as
needed in response to clinical presentation.
Follow-up assessments and outcome measures
Participants will complete up to three online assess-
ments: a baseline assessment and then at 12 weeks and
6 months after randomisation. Symptoms of depression
and anxiety will be assessed at each follow-up, and diag-
nostic interviews conducted at baseline and at 12 weeks.
At follow-ups, participants will be asked about any
changes in medication or other treatment that they may
have received since they started the trial.
The primary outcome is level of symptoms of
depression as assessed by change in Patient Health
Questionnaire-9 score (PHQ-9) [38] from randomisa-
tion baseline to 12 weeks in the Intention-To-Treat
population that involved all patients who were
randomly assigned. Secondary outcomes include levels
of anxiety as assessed by the Generalized Anxiety
Disorder-7 (GAD-7) [43], and social, home and work
functioning as assessed by the Work and Social
Adjustment Scale (WSAS) [52].
In addition, participants will complete a series of
self-report questionnaires designed to capture the
primary mechanism which each treatment compo-
nent is hypothesized to most strongly influence,
including rumination (5-item Brooding scale) [41],
change in habitual coping (adapted Self-Report Habit
Index) [53] (SRHI), overgeneralization (adapted Atti-
tudes to Self Scale – Revised) [54], self-compassion
[55], negative thinking (Automatic Thoughts Ques-
tionnaire) [56], increased behavioural activity and
reduced avoidance (Behavioural Activation for De-
pression Scale Short-form) [57], and absorption and
engagement in positive activities, adapted from mea-
sures of “flow” [58]. These variables will be tested in
mediational analyses.
Each assessment will take place via a telephone inter-
view, with the option of the questionnaire measures
being returned by online electronic survey, email or
post. To increase participant retention and completion
of follow-ups, multiple attempts and multiple means
(email, telephone, post) will be used to contact partici-
pants. Additionally, to increase motivation to complete
the follow-up measures, lottery draws for online shop-
ping vouchers will be held, with each participant receiv-
ing one ticket per completed follow-up. Research data
will be collected in an anonymised manner by means of
the interviews, online questionnaires or postal paper
questionnaires. Questionnaires from respondents who
prefer a paper version will be entered into the data
system by a research assistant. An administrative data-
base is used to ensure timely assessments. The majority
of data will be collected electronically and downloaded
automatically to reduce errors and missing data. Infor-
mation in the internet intervention is password pro-
tected, on secure encrypted servers using SSL. Each
participant included in the trial will be assigned a unique
identifier and all data stored without identifying details.
Contact details (name, email, telephone number, GP) are
stored separately to enable follow-up contacts and man-
agement of clinical risk. Data will be held on a secure
database on a password-protected computer. Access to
data will be restricted to the research team.
Statistical analysis plan
Data cleaning will follow the protocol set out by
Tabachnick and Fidell [59] including range checks for
data values. Statistical reporting will follow CON-
SORT standards [60]. Missing data will be inspected
and handled via full information maximum likelihood
(FIML) or multiple imputations (MI) as appropriate.
Primary analyses will be conducted on the Intention-
To-Treat (ITT) sample. A full, detailed analysis plan,
including plans for any interim analysis, subgroup
analysis, and sensitivity analysis of the primary
outcomes, will be prepared and finalised before the
analysis.
The primary outcome is change in PHQ-9 score from
randomisation baseline to 12 weeks in the intention-to-
treat population that involved all patients who were
randomly assigned. Secondary outcomes include GAD-7
and process-mechanism measures.
Our analysis will be an Analysis of Covariance (or
equivalent regression or growth curve models) for the
primary and secondary endpoints. Each main effect will
be modelled as a fixed effect, with baseline PHQ-9 as
the covariate. Our interest is primarily in tests of
ANOVA main effects and interactions. Main effects and
interactions are estimated based on aggregates across
experimental conditions (see Fig. 1). Models will be
fitted using generalized linear mixed models or latent
growth curve modelling, equivalent to ANCOVA regres-
sion models, adjusted for stratification variables and
baseline outcome values.
Under sub-optimal adherence, subsequent analyses
will use the Complier Average Causal Effect (CACE)
analysis, which assumes that under true randomization,
the probability of non-compliance in those randomized
to the absence of a treatment component is the same as
that observed in those randomized to the presence of a
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treatment component, and merely offering the treatment
component has no bearing on the outcome, i.e.
randomization has no direct effect on outcome but rather
outcome depends on the nature of compliance [61, 62]. It
therefore provides estimates of a treatment effect taking
into account adherence and compliance with the treat-
ment, whilst retaining the benefits of randomisation. It is
an example of using an Instrumental Variable (IV) where
randomisation is the instrument, which is correlated with
compliance to the treatment, and directly unrelated to the
outcome. Since randomization will be done to multiple
treatment components, which will create several latent
classes of compliance, we will use Maximum Likelihood
(ML) based Simultaneous Equation Model (SEM) to apply
such an IV approach.
Mediation and moderation analysis
Mediational analyses will be used to test the hypotheses
that each treatment component primarily works through
the hypothesized mechanism-of-action, using the ap-
proach outlined by Kraemer et al. [63]. We will use
modern causal inference methods including SEM to test
for mediation of the treatment components on depression
through changes in negative thinking, avoidance, approach
behaviours, rumination, compassion, etc. Analyses will
adjust for baseline measures of the mediator, outcomes,
and putative measured confounders and non-linear tests
along with bootstrapped standard error will be carried out
to test the mediation effect. In addition, we will investigate
potential moderation of the treatment components by site,
age, sex, severity of depression, co-morbid illness and
antidepressant use.
Ethics and Governance
Ethical and professional guidelines will be followed at all
times, in line with Good Clinical Practice guidelines.
Any possible adverse events witnessed by researchers or
the therapists will be discussed as soon as possible with
the principal investigator. If this is deemed to be an
adverse event, an adverse event report will be completed.
In the case of serious adverse events, the University of
Exeter, as sponsor, will also be notified using the same
report. Any suicidal risk reported during assessment
interviews or using the internet platform is assessed
using a well-established protocol to ensure that appro-
priate clinical support is provided. Users of the internet
treatment are provided with links to online support,
access to secure messaging to trial team, and automatic
signposting to help and guidance if reporting risk within
the intervention. A Trial Steering Committee has been
created with experts in depression, internet treatment
and clinical trials, and lived experience representatives,
to monitor and supervise the progress of the trial, to
provide oversight of the trial, including determining if
interim analyses are necessary and evaluating such data,
to consider any safety issues for the trial and recom-
mend appropriate contingencies, and to ensure that it is
being conducted in accordance with the principle of
Good Clinical Practice and the relevant regulations. All
patients are able to discontinue the internet treatment
by their own choice whenever they wish.
Discussion
The current trial has been designed to provide the
first examination of the underlying active treatment
components within internet CBT for depression, by
using a factorial experimental design. Understanding
the active components of therapy will enhance our
understanding of therapeutic mechanisms and poten-
tially enable the systematic building of more effective
interventions.
The current trial involves the optimisation stage in the
MOST process in which a screening experiment is
conducted to identify active components within internet
CBT for depression. In further research stages, this infor-
mation could be used to develop an optimised intervention
and to then evaluate its efficacy in a comparative rando-
mised controlled trial with existing recommended treat-
ments. If this approach indicates that some but not all
components within internet CBT for depression have a
significant effect size in reducing depression, it will lead to
the building of better therapies that focus on the active
ingredients and discard inert or iatrogenic elements. We
believe that this innovative approach may provide a useful
means to address recent requests for rigorous study designs
to determine which elements within psychological interven-
tions are critical [12].
Trial status
The trial was registered at Current Controlled Trials
ISRCTN number: ISRCTN24117387. Recruitment began
in July 2015 and was ongoing at time of submission.
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